ING Group
URGN icon

ING Group’s UroGen Pharma URGN Stock Holding History

ING Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$91.7M Buy
+180,000
New +$7.72M 0.52% 41

Other funds holding URGN

Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Migdal Insurance & Financial Holdings
Migdal Insurance & Financial Holdings Petach Tikva, Israel $16.3B AUM 54.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ING Group's URGN Position: Q3 2026 in Review

ING Group opened a new position in UroGen Pharma (URGN) in Q3 2026: 180,000 shares worth $91.7M. The stake represents 0.52% of the portfolio and ranks #41 among its holdings.

82 funds tracked by Wall St. Rank hold URGN as of Q3 2026.

  • ING Group held 180,000 shares of UroGen Pharma worth $91.7M as of Q3 2026.
  • UroGen Pharma was a new ING Group position in Q3 2026.
  • UroGen Pharma made up 0.52% of ING Group's portfolio in Q3 2026, its #41 holding.
  • 82 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2026.

Based on ING Group's 13F filing for Q3 2026, filed 10 Nov 2026.